Molecular Mechanisms and Intervention of Immunological Diseases.

免疫疾病的分子机制和干预。

基本信息

  • 批准号:
    08282101
  • 负责人:
  • 金额:
    $ 38.46万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research on Priority Areas
  • 财政年份:
    1996
  • 资助国家:
    日本
  • 起止时间:
    1996 至 2000
  • 项目状态:
    已结题

项目摘要

Immunological research has been a dual challenge for immunologists and physicians : discovering regulatory mechanism of the complex immune system, and determining how these discoveries may be applied to cure diseases or improve the health mankind. For the last 25 years, tremendous progress has been made in immunological research and clarified components involved in the immune regulation, including genes for antigen receptor and cytokine and its receptor, molecules for MHC gene products and costimulatory signals, and cells in lymphoid and non-lymphoid lineage. Recent advances on embryonic stem cell technology have enabled us to generate numerous numbers of various transgenic and gene-targeted mice. Some of gene-targeted mice provide us a useful tool for evaluating immunological disorders as human models. It is also true that the immune response to endogenous antigen as well as exogenous one trigger the onset of disease such as allergy, autoimmune disease, and severe chronic inflammatory … More disease. More than 10% of total Japanese population suffer from some allergy against environmental allergen such as cedar pollen and house-dust mite. However, it is still remained suffering how we prevent and cure from allergic diseases by immunological maneuver. Many of allergy patients and physicians easily tend to use non-specific inflammatory drugs such as glucocorticoid to treat allergic diseases.Aims of this research project supported by Grant-in-Aid for core research was to clarify molecular mechanisms and intervention of immunological disorders. We built up four major research groups to accomplish our aims and task each one of which investigated the following project. These are repertoire selection mechanism in early lymphoid development, mechanism of immunological diversity and tolerance and its break-down, mechanism of signaling pathway and its abnormality through antigen and cytokine receptor and costimulatory molecules, and intervention of immunological diseases. For four-year term, a number of exciting results were published in the international journals related in immunology field and in other related fields as well. For example, (1) experimental system to monitor for lymphoid-lineage development from bone marrow stem cells has been established and clarified that B and T cell progenitors are derived from pluripotent stem cells, but not from common lymphoid progenitors. (2) Novel molecules of Toll-like receptor (TLR) family (TLR6 through 11, RP105, and others) and related signaling molecules (MyD88, MD-1, MD-2, and others) were idnetified and their functions were clarified by generating gene knocked-out mice. Results revealed that TLR plays a critical role in protecting host against bacterial infection. (3) Novel signaling molecules coupled with BCR such as BLNK/BASH, with TCR such as pre-TCRα, and with cytokine receptor such as STAM, JAB/SSI-1, CIS, Smad6/7 were cloned and function of each member of molecules were clarified by generating gene-targeting. Intriguing molecular interaction between cytokine signaling molecule and TGF-β receptor signaling molecule was discovered. (4) Role of Btk in human and mouse in B cell development were clarified and mutations of Btk in each of Japanese XLA patients were identified. Role of IL-5 in allergy and mucosal immunology was disclosed and feasibility of anti-IL-5 mAb in preventing allergic asthma was evaluated using allergic guinea pig model. Less
免疫学研究一直是免疫学家和医生面临的双重挑战:发现复杂免疫系统的调节机制,并确定这些发现如何应用于治疗疾病或改善人类健康。近25年来,免疫学研究取得了巨大进展,阐明了参与免疫调节的组分,包括抗原受体和细胞因子及其受体基因、MHC基因产物和共刺激信号分子、淋巴和非淋巴细胞系细胞。胚胎干细胞技术的最新进展使我们能够产生大量的各种转基因和基因靶向小鼠。一些基因靶向小鼠为我们提供了一个有用的工具,评估免疫疾病作为人类模型。对内源性抗原和外源性抗原的免疫应答触发疾病的发作,如变态反应、自身免疫性疾病和严重的慢性炎症,这也是事实。 ...更多信息 疾病超过10%的日本总人口患有对环境过敏原的过敏,如雪松花粉和屋尘螨。然而,如何通过免疫策略来防治变态反应性疾病,仍是一个亟待解决的问题。许多变态反应患者和医生容易倾向于使用非特异性炎症药物如糖皮质激素来治疗变态反应性疾病,本研究项目的目的是阐明免疫紊乱的分子机制和干预措施。为了完成我们的目标和任务,我们成立了四个主要的研究小组,每个小组都对以下项目进行了研究。这些机制包括:早期淋巴发育中的库选择机制、免疫多样性和免疫耐受机制及其破坏机制、通过抗原和细胞因子受体及共刺激分子介导的信号通路及其异常机制、免疫性疾病的干预机制。在四年的任期内,在免疫学领域和其他相关领域的国际期刊上发表了许多令人兴奋的成果。例如,(1)已经建立了监测来自骨髓干细胞的淋巴系发育的实验系统,并阐明了B和T细胞祖细胞来源于多能干细胞,而不是来源于普通淋巴祖细胞。(2)Toll样受体(TLR)家族的新分子(TLR 6至11、RP 105等)和相关信号分子(MyD 88、MD-1、MD-2等)通过产生基因敲除小鼠被鉴定并阐明了它们的功能。结果显示TLR在保护宿主免受细菌感染方面起关键作用。(3)克隆了与BCR偶联的新型信号分子如BLNK/BASH,与TCR偶联的新型信号分子如pre-TCRα,与细胞因子受体偶联的新型信号分子如STAM、JAB/SSI-1、CIS、Smad 6/7,并通过产生基因靶向阐明了分子中每个成员的功能。细胞因子信号分子和TGF-β受体信号分子之间的相互作用被发现。(4)阐明了人和小鼠中Btk在B细胞发育中的作用,并鉴定了每个日本XLA患者中的Btk突变。本研究旨在揭示IL-5在变态反应和黏膜免疫中的作用,并利用豚鼠过敏性哮喘模型评价抗IL-5单克隆抗体预防过敏性哮喘的可行性。少

项目成果

期刊论文数量(78)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Kawamoto, H., T.Ikawa, Y.Katsura, et al.: "T cell progenitors emerge earlier than B cell progenitors in the murine fetal liver."Immunity. 12. 441-450 (2000)
Kawamoto, H.、T.Ikawa、Y.Katsura 等人:“在小鼠胎儿肝脏中,T 细胞祖细胞比 B 细胞祖细胞出现得更早。”免疫。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Nakashima M., K.Sonoda, and T.Watanabe.: "Inhibition of cell growth and induction of apoptotic cell death by a novel human tumor associated antigen, RCAS1"Nature Medicine. 5. 938-942 (1999)
Nakashima M.、K.Sonoda 和 T.Watanabe.:“新型人类肿瘤相关抗原 RCAS1 抑制细胞生长并诱导细胞凋亡”《自然医学》。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Saitoh,M.et al.: "Identification of important regions in the cytoplasmic juxtamembrane domain of type I receptor that separate signaling pathway of TGF-β" J.Biol.Chem.271. 2769-2775 (1996)
Saitoh, M. 等人:“I 型受体细胞质近膜结构域中分离 TGF-β 信号传导途径的重要区域的鉴定”J.Biol.Chem.271 2769-2775 (1996)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Tsukamoto, N., M.Hattori, N.Minato, et al.: "SPA-1 negatively regulates cell adhesion through GAP activity for Rap 1"J.Biol.Chem.. 274. 18463-18469 (1999)
Tsukamoto, N.、M.Hattori、N.Minato 等人:“SPA-1 通过 Rap 1 的 GAP 活性负向调节细胞粘附”J.Biol.Chem.. 274. 18463-18469 (1999)
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Yoshida, T., K.Ikuta, S.Takaki, K.Takatsu, et al.: "Defective B-1 cells development and impaired immunity against Angiostrongylus cantonensis in IL-5Rα deficient mice."Immunity. 4. 483-494 (1996)
Yoshida, T.、K.Ikuta、S.Takaki、K.Takatsu 等人:“IL-5Rα 缺陷小鼠中 B-1 细胞发育缺陷和针对广州管圆线虫的免疫力受损。”免疫。 1996)
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TAKATSU Kiyoshi其他文献

TAKATSU Kiyoshi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TAKATSU Kiyoshi', 18)}}的其他基金

Analysis of innate IL-5 producing cells in immune responses and chronic inflammation
免疫反应和慢性炎症中先天性 IL-5 产生细胞的分析
  • 批准号:
    24390119
  • 财政年份:
    2012
  • 资助金额:
    $ 38.46万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Spatiotemporal control of allergy and non-infectious inflammation and their regulation by natural products
过敏和非感染性炎症的时空控制及其天然产物的调节
  • 批准号:
    23659247
  • 财政年份:
    2011
  • 资助金额:
    $ 38.46万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Roles of cytokines and TLRs in lymphocyte activation and differentiation
细胞因子和 TLR 在淋巴细胞活化和分化中的作用
  • 批准号:
    20390141
  • 财政年份:
    2008
  • 资助金额:
    $ 38.46万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Enhancement of Th1 and antitumor immunity by Ag85B and Peptide-25.
Ag85B 和 Peptide-25 增强 Th1 和抗肿瘤免疫力。
  • 批准号:
    17013024
  • 财政年份:
    2005
  • 资助金额:
    $ 38.46万
  • 项目类别:
    Grant-in-Aid for Scientific Research on Priority Areas
Investigation of regulatory mechanisms for homeostasis and activation of lymphocyte
淋巴细胞稳态和激活调节机制的研究
  • 批准号:
    16109004
  • 财政年份:
    2004
  • 资助金额:
    $ 38.46万
  • 项目类别:
    Grant-in-Aid for Scientific Research (S)
REGULATORY MECHANISMS OF IL-5 DEPENDENT IMMUNE REGULATION
IL-5依赖性免疫调节的调节机制
  • 批准号:
    13307012
  • 财政年份:
    2001
  • 资助金额:
    $ 38.46万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
Molecular mechanisms of isotype switch recombination.
同型转换重组的分子机制。
  • 批准号:
    11470083
  • 财政年份:
    1999
  • 资助金额:
    $ 38.46万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B).
Molecular mechanisms of oral immunity : Role of IL-5 in potentiation of IgA production in mucosal lymphoid cell
口腔免疫的分子机制:IL-5 在增强粘膜淋巴细胞 IgA 产生中的作用
  • 批准号:
    10557036
  • 财政年份:
    1998
  • 资助金额:
    $ 38.46万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Molecular mechanisms of proliferation and differentiation of germinal center B cells
生发中心B细胞增殖分化的分子机制
  • 批准号:
    09470091
  • 财政年份:
    1997
  • 资助金额:
    $ 38.46万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Signaling through surface receptors in immune cells.
通过免疫细胞表面受体发出信号。
  • 批准号:
    09044263
  • 财政年份:
    1997
  • 资助金额:
    $ 38.46万
  • 项目类别:
    Grant-in-Aid for international Scientific Research

相似海外基金

I-Corps: Chimeric Antigen Receptor T Cell Manufacturing for Cancer Therapies
I-Corps:用于癌症治疗的嵌合抗原受体 T 细胞制造
  • 批准号:
    2403974
  • 财政年份:
    2024
  • 资助金额:
    $ 38.46万
  • 项目类别:
    Standard Grant
Improving Chimeric Antigen Receptor (CAR) T-Cell Therapy Using Engineering Biology and Mechanobiological Approach
利用工程生物学和力学生物学方法改进嵌合抗原受体 (CAR) T 细胞疗法
  • 批准号:
    10074571
  • 财政年份:
    2023
  • 资助金额:
    $ 38.46万
  • 项目类别:
    Grant for R&D
Development of canine chimeric antigen receptor-T cell that converts exhaustion-inducing signals into activation signals
开发犬嵌合抗原受体 T 细胞,将疲劳诱导信号转化为激活信号
  • 批准号:
    22KJ2967
  • 财政年份:
    2023
  • 资助金额:
    $ 38.46万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Delineating mechanisms underlying the enhanced stability and functionality of CD2-KO Tregs and chimeric antigen receptor (CAR) Tregs and their application in xenotransplantation
描述 CD2-KO Tregs 和嵌合抗原受体 (CAR) Tregs 稳定性和功能增强的机制及其在异种移植中的应用
  • 批准号:
    10646753
  • 财政年份:
    2023
  • 资助金额:
    $ 38.46万
  • 项目类别:
ICF: Chimeric antigen receptor T cells targeting CD123, CD33 and CLL1 for therapy of Acute Myeloid Leukaemia
ICF:靶向 CD123、CD33 和 CLL1 的嵌合抗原受体 T 细胞用于治疗急性髓系白血病
  • 批准号:
    MR/X03030X/1
  • 财政年份:
    2023
  • 资助金额:
    $ 38.46万
  • 项目类别:
    Research Grant
Development of novel combination therapy of chimeric antigen receptor T cells and HMG-CoA reductase inhibitors (statin)
嵌合抗原受体T细胞和HMG-CoA还原酶抑制剂(他汀类药物)的新型联合疗法的开发
  • 批准号:
    23K15306
  • 财政年份:
    2023
  • 资助金额:
    $ 38.46万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Generation of chimeric antigen receptor T cells using antibodies derived from colon cancer tumor-associated B cells.
使用源自结肠癌肿瘤相关 B 细胞的抗体生成嵌合抗原受体 T 细胞。
  • 批准号:
    23K15473
  • 财政年份:
    2023
  • 资助金额:
    $ 38.46万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
strategic research and development of chimeric antigen receptor T cell therapy in solid tumors
实体瘤嵌合抗原受体T细胞疗法的战略研发
  • 批准号:
    23K06783
  • 财政年份:
    2023
  • 资助金额:
    $ 38.46万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
In vivo transformation of chimeric antigen receptor B cells for a functional cure of HIV
嵌合抗原受体 B 细胞的体内转化用于 HIV 功能性治愈
  • 批准号:
    10594208
  • 财政年份:
    2023
  • 资助金额:
    $ 38.46万
  • 项目类别:
Optimizing outcomes for children and young adults with relapse of B-cell acute lymphoblastic leukemia after CD19-targeted chimeric antigen receptor T-cell therapy
优化 CD19 靶向嵌合抗原受体 T 细胞治疗后 B 细胞急性淋巴细胞白血病复发的儿童和年轻人的结局
  • 批准号:
    10572071
  • 财政年份:
    2023
  • 资助金额:
    $ 38.46万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了